Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]

• Main Authors: Ranzenigo M (Author), Gianotti N (Author), Galli L (Author), Poli A (Author), Mastrangelo A (Author), Bruzzesi E (Author), Chiurlo M (Author), Nozza S (Author), Bossolasco S (Author), Spagnuolo V (Author), Mancusi D (Author), Termini R (Author), Carini E (Author), Lazzarin A (Author), Castagna A (Author)
• Format: Book
• Published: Dove Medical Press, 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Ranzenigo M, Gianotti N, Galli L, et al. Drug Des Devel Ther. 2022;16:1975–1982. Page 1975, Abstract, Results, line five, the text “the ongoing regimen was based on NNRTIs in 37 (35%) and on InSTIs in 69 (65%)” should read “the ongoing regimen was based on NNR...